Naveen Pemmaraju: Addition of navitoclax to ruxolitinib for patients with myelofibrosis
Naveen Pemmaraju, Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a recent article by him and colleagues on LinkedIn:
“New online paper now available at Blood Neoplasia by American Society of Hematology from our international MPN group. Longer-term results and continued evidence for Disease Modification with focus addition of Navitoclax and BCLxL inhibition in patients with Myelofibrosis.”
Authors: Naveen Pemmaraju, Tim C.P. Somervaille, Francesca Palandri, Claire Harrison, Rami S. Komrokji, Andrew Perkins, Rosa M. Ayala Diaz, David Lavie, Akihiro Tomita, Yang Feng, Qin Qin, Jason Harb, Akshanth R. Polepally, Jalaja Potluri and Jacqueline S. Garcia
Naveen Pemmaraju is a Professor and Director of the BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of the MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN, and AML.
More posts featuring Naveen Pemmaraju.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023